What is the recommended peri‑operative glucocorticoid replacement regimen after craniotomy for a pituitary adenoma?

Peri-operative Glucocorticoid Management for Pituitary Adenoma Craniotomy

For patients undergoing craniotomy for pituitary adenoma with secondary adrenal insufficiency or at risk for it, administer hydrocortisone 100 mg IV at induction followed immediately by continuous infusion of 200 mg/24h, then continue 200 mg/24h IV postoperatively while NPO, transitioning to double-dose oral hydrocortisone for 48 hours to one week once tolerating enteral intake. 1

Intra-operative Management

The 2020 UK guidelines from the Association of Anaesthetists, Royal College of Physicians, and Society for Endocrinology provide the definitive framework for major surgery including craniotomy 1:

• At induction: Hydrocortisone 100 mg IV bolus
• Immediately after bolus: Start continuous infusion of hydrocortisone 200 mg over 24 hours
• Alternative option: Dexamethasone 6-8 mg IV (provides 24-hour coverage) 1

This regimen mimics the physiological stress response, where uncomplicated major surgery typically increases cortisol secretion five-fold to approximately 100 mg/day, with levels returning to baseline within 24-48 hours 1.

Postoperative Management

While NPO or with vomiting:

• Continue hydrocortisone 200 mg/24h IV infusion 1
• Alternative: Hydrocortisone 50 mg IM/IV every 6 hours 1

Once tolerating oral intake:

• Resume enteral hydrocortisone at double the usual replacement dose for 48 hours 1
• For uncomplicated recovery: Continue double-dose for 48 hours, then return to maintenance
• For complicated recovery or major surgery: May extend double-dose up to one week 1

Critical Decision Points

Pre-operative Assessment

The key distinction is whether the patient has pre-existing adrenal insufficiency (primary or secondary from pituitary disease):

• Known secondary AI or on chronic steroids ≥5 mg prednisolone equivalent for ≥4 weeks: Follow the above protocol 1
• Intact HPA axis pre-operatively: The evidence is more nuanced (see below)

For Patients with Intact Pre-operative HPA Axis

Recent research suggests a more selective approach may be safe 2, 3, 4, 5:

• Pre-operative cortisol ≥350 nmol/L (12.6 μg/dL): May not require peri-operative glucocorticoids 3
• Lower-dose option: 50 mg hydrocortisone intraoperatively alone (without postoperative dexamethasone) reduces unnecessary continuation 5
• Postoperative day 2-3 cortisol ≥250 nmol/L (9.1 μg/dL): Predicts eucortisolism and may not require discharge steroids 4
• Postoperative cortisol ≥357 nmol/L: 100% negative predictive value for adrenal insufficiency 6

However, a 2025 study found routine preoperative steroids in patients with normal HPA axis increased composite complications (58.3% vs 33.3%, p=0.004), particularly diabetes insipidus (52.5% vs 28.2%, p=0.006), with adjusted OR 2.90 for complications 7.

Practical Algorithm

For Known Secondary Adrenal Insufficiency:

1. Induction: Hydrocortisone 100 mg IV → immediate 200 mg/24h infusion
2. Postoperative: Continue 200 mg/24h IV while NPO
3. When tolerating PO: Double-dose oral hydrocortisone × 48h minimum (up to 1 week if complicated)
4. Then: Return to maintenance dosing

For Intact Pre-operative HPA Axis (Selective Approach):

1. Check pre-operative 0800h cortisol:
   • If ≥350 nmol/L (12.6 μg/dL): Consider 50 mg hydrocortisone at induction only
   • If <350 nmol/L: Use full protocol above
2. Postoperative day 2-3: Check morning cortisol
   • If ≥250 nmol/L (9.1 μg/dL) AND clinically well: Discharge without steroids
   • If <250 nmol/L OR symptomatic: Continue hydrocortisone replacement
3. Retest at 6-12 weeks with morning cortisol or short synacthen test

Important Caveats

Risk of adrenal crisis: The primary concern is preventing life-threatening adrenal crisis, which justifies the guideline-based approach of treating all patients as if they have secondary AI 1. The physiological stress of craniotomy is substantial.

Clinical monitoring is essential: Even with cortisol >250 nmol/L, two cases in one study required long-term replacement despite meeting biochemical thresholds 4. Daily clinical assessment for hypotension, dizziness, nausea, or other signs of adrenal insufficiency is mandatory.

Avoid over-suppression: High-dose dexamethasone postoperatively may unnecessarily suppress the HPA axis and increase complications 5, 7. If using the selective approach, avoid routine postoperative dexamethasone.

Pituitary-specific considerations: Pituitary surgery uniquely risks both immediate postoperative AI and delayed recovery of the HPA axis. The conservative guideline-based approach prioritizes safety over minimizing steroid exposure 1.